FDA approves Allergan combo eye drop for glaucoma

NEW YORK, Oct 31 (Reuters) - Allergan Inc (AGN.N) on Wednesday said U.S. regulators approved its glaucoma drug Combigan, an eye drop which treats the potentially blinding eye condition with two drugs that work through different mechanisms.

Allergan, best known for its Botox anti-wrinkle drug but also a leading provider of eye medications and products, said its new drug would be introduced in the fourth quarter of 2007.

The company said Combigan would combine "two strong agents in one bottle" -- brimonidine and timolol -- to control pressure within the eye that can harm the optic nerve. (Reporting by Ransdell Pierson, editing by Gerald E. McCormick)